106 results
8-K
EX-10.2
TNFA
TNF Pharmaceuticals Inc.
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
and to maintain asset and liability accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance … and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification except
8-K
EX-10.1
TNFA
TNF Pharmaceuticals Inc.
21 May 24
MyMD Pharmaceuticals Secures Strategic Investments
9:10am
as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability accountability, (iii) access … Data from unauthorized use, access, misappropriation or modification except in each case, where such would not, either individually or in the aggregate
8-K
EX-3.2
jr1jkjkmhn x5jjjpr
7 Mar 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-99.1
oe6yin
6 Dec 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
vjd 2tck8
3 Aug 23
MyMD Pharmaceuticals Phase 2 Trial Update
4:30pm
8-K
EX-99.1
et0fdovr56c1ri3n oa6
18 Nov 22
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
4:30pm
8-K
EX-99.1
c7lccdet
14 Nov 22
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Data Research
8:32am